Sarepta Therapeutics, Inc.

Free In-Depth Equity Research Report

Sarepta Therapeutics shares declined 0.09 percent to close at $23.28 a share Thursday. The stock traded between $22.34 and $24.60 on volume of 5.05 million shares traded. On March 14th, Sarepta announced the U.S. Food and Drug Administration’s Peripheral and Central Nervous System (PCNS) Drugs Advisory Committee will review Sarepta’s New Drug Application (NDA) for eteplirsen on April 25, 2016. Shares of Sarepta Therapeutics have fallen approximately 40.0 percent year-to-date, but have rallied roughly 20.0 percent in the past week.

Going forward ... (see research report)

fanned_report

Access Your Sarepta Therapeutics, Inc. Report Now!